Esperion Therapeutics, Inc. announced that the Bundeskartellamt has cleared its proposed merger with Essence Parent Inc., an affiliate of ArchiMed SAS. The merger, which would make Esperion a wholly-owned subsidiary of Parent, remains subject to closing conditions including Hart-Scott-Rodino Antitrust Improvement Act waiting periods and stockholder approval at a special meeting scheduled for July 8, 2026. Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cardiovascular disease.
